Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase
Observational
Started
2019-01-01
Last updated
2025-07-20
Condition(s) studied
Esophageal Squamous Cell Cancer (SCC)Recurrent Laryngeal Nerve PalsyDeep LearningPostoperative Complication
Study summary
The goal of this observational study is to develop a predictive model for left recurrent laryngeal nerve (RLN) lymph node metastasis using deep learning algorithms. The model will be developed using clinical data from previous esophageal cancer surgeries, including preoperative CT imaging, and histopathological images from gastroscopic biopsies. The model will also be validated through prospective clinical trials to guide the intraoperative lymph node dissection, thereby reducing postoperative risks of RLN injury.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Preoperative gastroscopic biopsy confirmed esophageal squamous cell carcinoma;
* The patient underwent esophagectomy with lymph nodes dissection along the left recurrent laryngeal nerve.
Exclusion Criteria:
* The patient's medical records are incomplete;
* The patient refused to participate in the trial.
Primary outcome measure(s)
AUROC (Area Under the Receiver Operating Characteristic Curve) — From enrollment to the end of treatment at 4 weeks The discriminant ability of the comprehensive evaluation model at different thresholds (positive vs. negative)
Trial sites (1)
Facility
City
Region
Status
Daping Hospital
Chongqing
China
More Daping Hospital and the Research Institute of Surgery of the Third Military Medical University trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.